<div class="container">

<table style="width: 100%;"><tr>
<td>CrinsEtAl2014</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Pediatric liver transplant example data</h2>

<h3>Description</h3>

<p>Numbers of cases (transplant patients) and events (acute rejections,
steroid resistant rejections, PTLDs, and deaths) in experimental and control groups of
six studies.</p>


<h3>Usage</h3>

<pre><code class="language-R">data("CrinsEtAl2014")</code></pre>


<h3>Format</h3>

<p>The data frame contains the following columns:
</p>

<table>
<tr>
<td style="text-align: left;">
    <b>publication</b>         </td>
<td style="text-align: left;"> <code>character</code> </td>
<td style="text-align: left;"> publication identifier (first author and publication year) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>year</b>                </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> publication year </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>randomized</b>          </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> randomization status (y/n) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.type</b>        </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> type of control group (‘concurrent’ or ‘historical’)</td>
</tr>
<tr>
<td style="text-align: left;">
    <b>comparison</b>          </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> type of comparison (‘IL-2RA only’, ‘delayed CNI’, or ‘no/low steroids’) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>IL2RA</b>               </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> type of interleukin-2 receptor antagonist (IL-2RA) (‘basiliximab’ or ‘daclizumab’) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>CNI</b>                 </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> type of calcineurin inhibitor (CNI) (‘tacrolimus’ or ‘cyclosporine A’) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>MMF</b>                 </td>
<td style="text-align: left;"> <code>factor</code>    </td>
<td style="text-align: left;"> use of mycofenolate mofetil (MMF) (y/n) </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>followup</b>            </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> follow-up time in months </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>treat.AR.events</b>     </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of AR events in experimental group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>treat.SRR.events</b>    </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of SRR events in experimental group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>treat.PTLD.events</b>   </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of PTLD events in experimental group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>treat.deaths</b>        </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of deaths in experimental group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>treat.total</b>         </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of cases in experimental group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.AR.events</b>   </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of AR events in control group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.SRR.events</b>  </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of SRR events in control group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.PTLD.events</b> </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of PTLD events in control group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.deaths</b>      </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of deaths in control group </td>
</tr>
<tr>
<td style="text-align: left;">
    <b>control.total</b>       </td>
<td style="text-align: left;"> <code>numeric</code>   </td>
<td style="text-align: left;"> number of cases in control group </td>
</tr>
<tr>
<td style="text-align: left;">
  </td>
</tr>
</table>
<h3>Details</h3>

<p>A systematic literature review investigated the evidence on the
effect of Interleukin-2 receptor antagonists (IL-2RA) and resulted in
six controlled studies reporting acute rejection (AR),
steroid-resistant rejection (SRR) and post-transplant
lymphoproliferative disorder (PTLD) rates as well as mortality in
pediatric liver transplant recipients.
</p>


<h3>Source</h3>

<p>N.D. Crins, C. Roever, A.D. Goralczyk, T. Friede.
Interleukin-2 receptor antagonists for pediatric liver transplant
recipients: A systematic review and meta-analysis of controlled
studies.
<em>Pediatric Transplantation</em>, <b>18</b>(8):839-850, 2014.
<a href="https://doi.org/10.1111/petr.12362">doi:10.1111/petr.12362</a>.
</p>


<h3>References</h3>

<p>C. Roever.
Bayesian random-effects meta-analysis using the bayesmeta R package.
<em>Journal of Statistical Software</em>, <b>93</b>(6):1-51, 2020.
<a href="https://doi.org/10.18637/jss.v093.i06">doi:10.18637/jss.v093.i06</a>.
</p>
<p>C. Roever, T. Friede.
Using the bayesmeta R package for Bayesian random-effects meta-regression.
<em>Computer Methods and Programs in Biomedicine</em>,
<b>299</b>:107303, 2023.
<a href="https://doi.org/10.1016/j.cmpb.2022.107303">doi:10.1016/j.cmpb.2022.107303</a>.
</p>
<p>T.G. Heffron et al.
Pediatric liver transplantation with daclizumab induction therapy.
<em>Transplantation</em>, <b>75</b>(12):2040-2043, 2003.
<a href="https://doi.org/10.1097/01.TP.0000065740.69296.DA">doi:10.1097/01.TP.0000065740.69296.DA</a>.
</p>
<p>N.E.M. Gibelli et al.
Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver
transplantation: comparative study.
<em>Transplantation Proceedings</em>, <b>36</b>(4):956-957, 2004.
<a href="https://doi.org/10.1016/j.transproceed.2004.04.070">doi:10.1016/j.transproceed.2004.04.070</a>.
</p>
<p>S. Schuller et al.
Daclizumab induction therapy associated with tacrolimus-MMF has better
outcome compared with tacrolimus-MMF alone in pediatric living donor
liver transplantation.
<em>Transplantation Proceedings</em>, <b>37</b>(2):1151-1152, 2005.
<a href="https://doi.org/10.1016/j.transproceed.2005.01.023">doi:10.1016/j.transproceed.2005.01.023</a>.
</p>
<p>R. Ganschow et al.
Long-term results of basiliximab induction immunosuppression in
pediatric liver transplant recipients.
<em>Pediatric Transplantation</em>, <b>9</b>(6):741-745, 2005.
<a href="https://doi.org/10.1111/j.1399-3046.2005.00371.x">doi:10.1111/j.1399-3046.2005.00371.x</a>.
</p>
<p>M. Spada et al.
Randomized trial of basiliximab induction versus steroid therapy in
pediatric liver allograft recipients under tacrolimus immunosuppression.
<em>American Journal of Transplantation</em>, <b>6</b>(8):1913-1921, 2006.
<a href="https://doi.org/10.1111/j.1600-6143.2006.01406.x">doi:10.1111/j.1600-6143.2006.01406.x</a>.
</p>
<p>J.M. Gras et al.
Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric
liver transplantation: Clinical and pharmacoeconomic study in 50 children.
<em>Liver Transplantation</em>, <b>14</b>(4):469-477, 2008.
<a href="https://doi.org/10.1002/lt.21397">doi:10.1002/lt.21397</a>.
</p>


<h3>See Also</h3>

<p><code>GoralczykEtAl2011</code>.
</p>


<h3>Examples</h3>

<pre><code class="language-R">data("CrinsEtAl2014")
## Not run: 
# compute effect sizes (log odds ratios) from count data
# (using "metafor" package's "escalc()" function):
require("metafor")
crins.es &lt;- escalc(measure="OR",
                   ai=exp.AR.events,  n1i=exp.total,
                   ci=cont.AR.events, n2i=cont.total,
                   slab=publication, data=CrinsEtAl2014)
print(crins.es)

# analyze using weakly informative half-Cauchy prior for heterogeneity:
crins.ma &lt;- bayesmeta(crins.es, tau.prior=function(t){dhalfcauchy(t,scale=1)})

# show results:
print(crins.ma)
forestplot(crins.ma)
plot(crins.ma)

# show heterogeneity posterior along with prior:
plot(crins.ma, which=4, prior=TRUE)

# perform meta analysis using 2 randomized studies only
# but use 4 non-randomized studies to inform heterogeneity prior:
crins.nrand &lt;- bayesmeta(crins.es[crins.es$randomized=="no",],
                         tau.prior=function(t){dhalfcauchy(t,scale=1)})
crins.rand  &lt;- bayesmeta(crins.es[crins.es$randomized=="yes",],
                         tau.prior=function(t){crins.nrand$dposterior(tau=t)})
plot(crins.nrand, which=4, prior=TRUE,
     main="non-randomized posterior = randomized prior")
plot(crins.rand, which=4, prior=TRUE, main="randomized posterior")
plot(crins.rand, which=1)

## End(Not run)
</code></pre>


</div>